HUTCHMED China Ltd (LON:HCM)
160p+0.79%
Spriggl Score: Weak— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Cash-rich biotech bets on pipeline approvals; leadership gap and operating losses remain key risks to watch.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and p…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - Specialty & Generic
- Market Cap:
- £1.4B
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across HUTCHMED China Ltd and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free